Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Summary

Objectives

Avelumab is a human immunoglobulin (Ig)G1 monoclonal antibody (mAb) directed against
programmed death ligand 1 (PD-L1). Avelumab selectively binds to PD-L1 and competitively
blocks its interaction with programmed death receptor 1 (PD-1), thereby interfering with
this key immune checkpoint inhibition pathway. Avelumab is currently being investigated
as single agent and in combination with other anti cancer therapies in patients with
locally advanced or metastatic solid tumors and various hematological malignancies.

Talazoparib is a potent, orally bioavailable poly (adenosine diphosphate [ADP] ribose)
polymerase (PARP) inhibitor, which is cytotoxic to human cancer cell lines harboring gene
mutations that compromise deoxyribonucleic acid (DNA) repair, an effect referred to as
synthetic lethality, and by trapping PARP protein on DNA thereby preventing DNA repair,
replication, and transcription.

Avelumab in combination with talazoparib will be investigated in patients with locally
advanced (primary or recurrent) or metastatic solid tumors with a BReast CAncer
susceptibility gene (BRCA)1, or BRCA2, or ataxia telangiectasia mutated (ATM) gene
defect.